WilmerHale Life Sciences Webinar: Building Effective 10b5-1 Trading Plans

  • 9.18.2014 | 12:00 PM - 1:00 PM


Michael Bongiorno , Cynthia Mazareas , Jonathan Wolfman

Regulators and prosecutors have become increasingly suspicious of corporate who could be abusing 10b5-1 plans when trading their own company stock. Life sciences companies may face particular challenges given stock volatility and clinical trial developments. Given this landscape, life sciences companies should strongly consider adopting a 10b5-1 plan to help protect their executives from allegations of , and companies that already have 10b5-1 plans should deploy safeguards and strategies to more effectively demonstrate compliance.

During this webinar, WilmerHale Partners Michael Bongiorno, Jonathan Wolfman and Special Counsel Cynthia Mazareas, discuss 10b5-1 plans and their value to public life sciences companies. Topics include:

– how Rule 10b5-1 works;
– whether or not companies should allow use of 10b5-1 plans;
– whether or not companies should require use of 10b5-1 plans;
– best practices for establishing a 10b5-1 plan; and
– whether or not companies should adherence to best practices.

View the Webinar Recording
View the Presentation Materials

California and non-transitional New York CLE credit offered to those who participated in the live webinar.